Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

@inproceedings{Sikirica2012CostEO,
  title={Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents},
  author={Vanja Sikirica and Moshe Haim Erder and Jipan Xie and Dendy S Macaulay and Melissa D Diener and Paul S. Hodgkins and Eric Qiong Wu},
  booktitle={PharmacoEconomics},
  year={2012}
}
Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in childhood, affecting 3–7% of school-age children in the US and imposing substantial economic burden. Stimulants are considered first-line pharmacological treatment and are the most prescribed treatment for ADHD. However, approximately 30% of children with ADHD do not have an optimal response to a single stimulant and may require adjunctive therapy. Our objective was to conduct a cost-effectiveness analysis (CEA… CONTINUE READING